Rectal or intramuscular diclofenac reduces the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography

Basit Öğe Kaydı
dc.authoridMurat Bıyık: 0000-0003-0558-2882
dc.authoridHüseyin Ataseven: 0000-0001-8515-8760
dc.authoridRamazan Uçar: 0000-0002-8656-4434
dc.contributor.authorBıyık, Murat
dc.contributor.authorAtaseven, Hüseyin
dc.contributor.authorUçar, Ramazan
dc.contributor.authorUçar, Esma
dc.contributor.authorPolat, İlker
dc.contributor.authorÇifçi, Sami
dc.date.accessioned2020-01-18T21:02:51Z
dc.date.available2020-01-18T21:02:51Z
dc.date.issued2016
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.descriptionWOS:000378646700017en_US
dc.descriptionPubMed ID:27513404en_US
dc.description.abstractBackground/aim: Acute pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography (ERCP). We aimed to evaluate the efficacy of intramuscular diclofenac sodium for prophylaxis of post-ERCP pancreatitis (PEP) in comparison to the rectal form. Materials and methods: One hundred and fifty consecutive patients who underwent ERCP were enrolled in this single-center, prospective, randomized controlled study. Patients were randomized into three groups. The first group received 75 mg of diclofenac sodium via intramuscular route and the second group received 100 mg of diclofenac sodium rectally 3090 min before the procedure. The third group served as the control group. Patients were evaluated for post-ERCP pancreatitis with serum amylase levels and abdominal pain 24 h after the procedure. Results: The overall incidence of PEP was 6% (n 9) and 2% (n 1) in the intramuscular (IM) and rectal groups, respectively, and 14% in the control group (P 0.014). Nineteen (12.7%) patients developed post-ERCP abdominal pain (8% in IM, 10% in rectal, and 20% in control group; P 0.154). Twenty-five (16.6%) patients developed post-ERCP hyperamylasemia (10% in IM, 12% in rectal, and 24% in control group; P 0.03). Conclusion: Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP pancreatitis.en_US
dc.identifier.citationBıtık, M., Ataseven, H., Uçar, R., Uçar E., Polat, I., Çifçi, S., Demir, A. (2016). Rectal or intramuscular diclofenac reduces the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography. Turkish Journal of Medical Sciences, 46, 4, 1059-1063.en_US
dc.identifier.doi10.3906/sag-1502-104en_US
dc.identifier.endpage1063en_US
dc.identifier.issn1300-0144en_US
dc.identifier.issn1303-6165en_US
dc.identifier.issue4en_US
dc.identifier.pmid27513404en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1059en_US
dc.identifier.urihttp://app.trdizin.gov.tr/publication/paper/detail/TWpRNU1UY3pNdz09
dc.identifier.urihttps://hdl.handle.net/20.500.12452/1317
dc.identifier.volume46en_US
dc.identifier.wosWOS:000378646700017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiclofenacen_US
dc.subjectERCPen_US
dc.subjectPost-ERCP Pancreatitisen_US
dc.titleRectal or intramuscular diclofenac reduces the incidence of pancreatitis after endoscopic retrograde cholangiopancreatographyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ramazan Uçar.pdf
Boyut:
77.74 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text/Tam Metin
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu